During the last session, Immunome Inc (NASDAQ:IMNM)’s traded shares were 1.97 million, with the beta value of the company hitting 2.03. At the end of the trading day, the stock’s price was $7.09, reflecting an intraday gain of 2.01% or $0.14. The 52-week high for the IMNM share is $26.70, that puts it down -276.59 from that peak though still a striking 2.12% gain since the share price plummeted to a 52-week low of $6.94. The company’s market capitalization is $616.48M, and the average intraday trading volume over the past 10 days was 1.1 million shares, and the average trade volume was 962.90K shares over the past three months.
Immunome Inc (IMNM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. IMNM has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.62.
Immunome Inc (NASDAQ:IMNM) trade information
Immunome Inc (IMNM) registered a 2.01% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.01% in intraday trading to $7.09, hitting a weekly high. The stock’s 5-day price performance is -17.27%, and it has moved by -26.68% in 30 days. Based on these gigs, the overall price performance for the year is -70.85%. The short interest in Immunome Inc (NASDAQ:IMNM) is 9.52 million shares and it means that shorts have 13.83 day(s) to cover.
The consensus price target of analysts on Wall Street is $33, which implies an increase of 78.52% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $23 and $35 respectively. As a result, IMNM is trading at a discount of -393.65% off the target high and -224.4% off the low.
Immunome Inc (IMNM) estimates and forecasts
In the rating firms’ projections, revenue will decrease -85.57% compared to the previous financial year.
As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.03M and 2.36M respectively. In this case, analysts expect current quarter sales to shrink by -100.00% and then drop by -100.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -38.15%. While earnings are projected to return 46.10% in 2025, the next five years will return 20.77% per annum.
IMNM Dividends
Immunome Inc is due to release its next quarterly earnings on 2025-Mar-18. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Immunome Inc (NASDAQ:IMNM)’s Major holders
Immunome Inc insiders own 17.68% of total outstanding shares while institutional holders control 57.67%, with the float percentage being 70.06%. REDMILE GROUP, LLC is the largest shareholder of the company, while 172.0 institutions own stock in it. As of 2024-06-30, the company held over 4.89 million shares (or 8.1579% of all shares), a total value of $59.16 million in shares.
The next largest institutional holding, with 4.21 million shares, is of FMR LLC’s that is approximately 7.0257% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $50.95 million.
Also, the Mutual Funds coming in first place with the largest holdings of Immunome Inc (IMNM) shares are T. Rowe Price Small-Cap Stock Fund, Inc. and T. Rowe Price Health Sciences Fund, Inc. . Data provided on Dec 31, 2024 indicates that T. Rowe Price Small-Cap Stock Fund, Inc. owns about 1.96 shares. This amounts to just over 2.25 percent of the company’s overall shares, with a $13.88 million market value. The same data shows that the other fund manager holds slightly less at 1.69, or about 1.95% of the stock, which is worth about $12.0 million.
